Subcutaneous Spesolimab Reduces GPP Flares: Phase 2 Study

For generalized pustular psoriasis, treatment with the subcutaneously administered IL-36 receptor antagonist resulted in a significant reduction in flares compared with placebo.

Related Keywords

Singapore ,Charleston ,South Carolina ,United States ,Japan ,Connecticut ,New Haven ,Yale University ,China ,Bruce Strober ,Todd Schlesinger ,European Union ,Boehringer Ingelheim ,Drug Administration ,World Congress ,Clinical Research Center ,Central Connecticut Dermatology ,Medscape Medical News ,Presented July ,